Navigation Links
Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule 'Revamilast'
Date:8/10/2011

an volunteers treated with Revamilast suggests a good ex-vivo inhibition of the inflammatory marker TNF-α with maximum inhibition upto 93%. Based on these results and animal model data, it is expected that Revamilast would be beneficial in a variety of inflammatory disorders. Additionally, Revamilast does not appear to be metabolized to carcinogenic metabolites (ADCP N-oxide and ADCP N-oxide epoxide); and plasma samples from a Phase 1 study analyzed for such metabolites of Revamilast, showed no levels were detected in human plasma.

With the completion of several Phase I studies, Glenmark has initiated a global Phase IIb trial for Revamilast in patients with Asthma. Glenmark has already received approval from respective authorities in the UK, Poland, India and Czech Republic to conduct Phase IIb studies. Regulatory submissions have also been completed in Russia. The primary objective of this 12-week, double blind, placebo controlled, dose range finding study is to evaluate the effects of Revamilast at three doses on lung function (FEV1) in nearly 450 patients with chronic persistent Asthma.

Glenmark has also initiated another global Phase IIb trial with Revamilast in patients with Rheumatoid Arthritis. Glenmark has already received approval from the MHRA, UK, India, Poland and the Philippines to conduct Phase IIb studies for Rheumatoid Arthritis. Regulatory submissions have also been completed in Sri Lanka. The objective is to determine the efficacy of three doses of Revamilast compared to placebo in the treatment of more than 400 patients with active Rheumatoid Arthritis who showed an inadequate response to methotrexate.

In parallel to these two clinical studies, Glenmark is also conducting various other clinical and non-clinical studies to ensure timely entry into Phase III trials. Glenmark intends to initiate Phase III trials for at least one indication in the second half of FY 2012-13

PDE4 inhibitors (Impact o
'/>"/>

SOURCE Glenmark Pharmaceuticals Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Glenmark Announces the Discovery of a Novel Chemical Entity GRC 17536, a TRPA1 Receptor Antagonist, a Potential First-in-Class Molecule Globally
2. Glenmarks Novel Molecule for Diabetes, Melogliptin to Enter Phase III Trials
3. SCRIP, the Leading Pharmaceutical Magazine in the World Crowns Glenmark as the "Best Pharma Company in the World - SME" and the "Best Company in Emerging Markets" at the SCRIP Awards 2008 in London
4. PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy
5. BioMarin Initiates Phase 1 Trial for BMN 673 in Patients With Advanced Hematological Malignancies
6. InterMune Initiates Phase 3 ASCEND Study of Pirfenidone in IPF
7. GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine
8. CrystalGenomics Initiates CG100649 Phase 2b Study in Patients with Osteoarthritis
9. Metabolex Initiates Phase 2 Trial of Arhalofenate
10. Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
11. TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 The Alliance ... a multi-stakeholder non-profit collaborative building a global system ... research, today announced Phase 3 of its Site ... , Amir H. Kalali, Vice-President, Global Head, Neuroscience ... President, Compliance and Quality Integration (CQI) Consulting will ...
(Date:9/16/2014)... can harvest energy from jaw movements has been created ... is hoped that the device can generate electricity from ... small-scale implantable or wearable electronic devices, such as hearing ... , The first results of the device,s performance have ... Smart Materials and Structures . , Jaw movements ...
(Date:9/16/2014)... to cars and flashlights, batteries play an important ... constantly are seeking ways to improve battery life ... a water-based solution, researchers at the University of ... nuclear battery that could be used for many ... automobiles and also in complicated applications such as ...
(Date:9/16/2014)... Sept. 16, 2014 Cardioxyl Pharmaceuticals, Inc. ... has been shown to be effective in animal models ... alternative to intravenous infusions that could pave the way ... were presented yesterday at the Heart Failure Society of ... Las Vegas . The ...
Breaking Biology Technology:Global Standards Initiative for Clinical Research Sites Advances 2Global Standards Initiative for Clinical Research Sites Advances 3Global Standards Initiative for Clinical Research Sites Advances 4'Smart material' chin strap harvests energy from chewing 2Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2
... Popular Emergency Department Information, System Also Includes Embedded Web ... ... DALLAS, Oct. 24 T-System, Inc., the leading provider of,clinical ... announced the release of The T SystemEV(R),2.6.3, the newest upgrade to ...
... JERUSALEM, October 24 IDenta Corp. (Other,OTC: IDTA.PK) ... penetration of the United States and Oversees markets., ... Corporation (Encino,CA) and IDenta Corporation continues, has resulted ... quarters of 2008. Accutest(R) IDenta sales,have increased significantly ...
... held October 29-31 at the Palace Hotel, San,Francisco, ... Group, the world,s,marketplace for expertise, and the Biotechnology ... the Seventh Annual BIO Investor,Forum. Featured therapeutic panels ... consultants along with executives from public and,private equity ...
Cached Biology Technology:T-System Releases The T SystemEV(R) 2.6.3, Featuring New Meds/Allergies Notification, Automated Charge Capture 2T-System Releases The T SystemEV(R) 2.6.3, Featuring New Meds/Allergies Notification, Automated Charge Capture 3International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees 2International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees 3International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees 4Gerson Lehrman Group and BIO Collaborate to Identify Scientific Expertise for the Seventh Annual BIO Investor Forum 2Gerson Lehrman Group and BIO Collaborate to Identify Scientific Expertise for the Seventh Annual BIO Investor Forum 3
(Date:9/17/2014)... retinoblastoma protein gene are a leading cause of eye ... fruit fly eyes to unlock the secrets of this ... on the cover of the current issue of the ... researchers provide the first detailed examination of a set ... cancer gene, said Irina Pushel, MSU undergraduate and co-author. ...
(Date:9/17/2014)... PROVIDENCE, R.I. [Brown University] After decades of decline, ... Cod,s saltmarshes. To the eye, the marsh in those ... clear that a key service of the marsh ... aesthetics back but the ecosystem function hasn,t come back," ... and senior author of the study in the journal ...
(Date:9/17/2014)... has learned a great deal about complex social behavior ... have something to teach too. , With their unusually ... cognition, parrots live in a complex social environment---not merely ... bees or ants, but in a dynamic setting of ... most intelligent mammals: dolphins, whales, primates, and social carnivores, ...
Breaking Biology News(10 mins):Abnormal properties of cancer protein revealed in fly eyes 2Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3Being social: Learning from the behavior of birds 2
... cell factor overexpressed both in brain tumor cells and ... inducing angiogenesis. The research study, published in the April ... cells and surrounding tissues and may have substantial significance ... the most lethal types of tumor, malignant gliomas. ...
... play an important role in regulating blood flow in ... assumptions underlying today's most sophisticated brain imaging techniques and ... understanding Alzheimer's disease. , In a paper to appear ... available on-line, scientists at the University of Rochester Medical ...
... the Virginia Bioinformatics Institute at Virginia Tech have ... range of microbial genome sequences. , The VBI ... recent article published in Nucleic Acids Research (Vol.34, ... the plant pathogens Phytophthora sojae and Phytophthora ramorum. ...
Cached Biology News:Growth factor-promoting angiogenesis expressed in tumor cells and normal neurons 2Blood flow in brain takes a twist, affecting views of Alzheimer's 2Blood flow in brain takes a twist, affecting views of Alzheimer's 3Virginia Bioinformatics Institutes launches microbial database 2